Influence of estrogen and polyamines on mifepristone-induced apoptosis in prostate cancer cells.
OBJECTIVE
Although androgens are the main steroids controlling the growth of prostate glands, estrogens are also important in the regulation of its growth. Prostate cancer cells, like other cancer cells, maintain high levels of polyamines. In LNCaP cells, apoptosis is induced by mifepristone. During the process of cell death, the regulation of ROS production, caspase-3 activation and poly (ADP-ribose) polymerase cleavage were investigated in the presence of estrogen and polyamines to identify their possible roles.


METHODS
The cell growth was assessed using the MTT assay, and the intracellular ROS production by the DCFH-DA assay. The p53 protein expression, activation of caspase-3 and PARP cleavage were checked by Western blotting, with specific antibodies to each.


RESULTS
The growth and viability of the cells were significantly inhibited, in a dose- and time-dependent manners, by mifepristone (MIF) treatment. The production of ROS were dependent on the MIF dosage. The activation of caspase-3 and cleavage of PARPalso increased with the duration of MIF treatment. The expression of p53 protein also increased with increases in the MIF incubation time. E(2) severely inhibited the ROS production, caspase-3 activation and PARP cleavage. However, polyamines only inhibited the ROS production, without influencing the caspase-3 activation or PARP cleavage.


CONCLUSIONS
In LNCaP cells, MIF induces apoptosis through ROS production. The expression of p53 protein, caspase-3 activation and PARP cleavage accompanied the process of apoptosis. The apoptotic processes were inhibited by E(2), but polyamines only inhibited the ROS production, implying the multifunctional role of E(2), in addition to its role as a free radical scavenger.
Choi
Eun Kyung
EK
Department of Biology, Pusan National University, Busan, Korea.
Song
Hwi-June
HJ
Park
Min S
MS
Kim
Byeong Gee
BG
EMBO J. 1999 Nov 1;18(21):6027-36
10545114
Prostate. 2000 Nov 1;45(3):232-7
11074525
J Cancer Res Clin Oncol. 2001 Sep;127(9):570-6
11570579
Anal Biochem. 1976 May 7;72:248-54
942051
Prostate. 1995 Apr;26(4):194-204
7716084
J Cell Biol. 1999 Jan 25;144(2):281-92
9922454
Am J Physiol. 1998 Jun;274(6):E1002-8
9611149
Cancer Res. 1999 Jan 15;59(2):382-90
9927051
Prostate. 2000 Apr 1;43(1):31-42
10725863
Biochem Biophys Res Commun. 1999 Jul 5;260(2):410-5
10403783
Endocr Relat Cancer. 2003 Jun;10(2):187-91
12790781
Am J Physiol Cell Physiol. 2000 Sep;279(3):C868-75
10942736
Mol Cancer Ther. 2002 Aug;1(10):831-40
12492116
Cancer Res. 2001 Feb 1;61(3):1227-32
11221855
Cancer Res. 1988 Feb 15;48(4):759-74
3123052
Nature. 1997 Sep 18;389(6648):300-5
9305847
Biochem Biophys Res Commun. 2001 Jun 1;284(1):203-10
11374891
Cancer Res Treat. 2001 Oct;33(5):385-91
26680812
Biochem Biophys Res Commun. 1998 Mar 6;244(1):298-303
9514920
Cancer Chemother Pharmacol. 1998;41(6):505-12
9554596